Neural Substrates Mediating Amphetamine Responses

  • Susan D. Iversen
Part of the Advances in Behavioral Biology book series (ABBI, volume 21)


In a range of species amphetamine produces highly characteristic changes in behaviour. Rats have been studied most intensively, and in this species low doses (1.5mg/kg) of d-amphetamine induce a persistent running or locomotor behaviour. Higher doses (5mg/kg) lead to a disruption of motor behaviour, described as stereotyped, in which elements of the normal motor repertoire, such as sniffing, rearing, licking, biting and gnawing, are repeated in both abnormal order and frequency. In practical terms these behaviours are easy to quantify; and, very largely for this reason, amphetamine has often been selected as the “model” drug in experiments designed to elucidate the modes of action of stimulants.


Substantia Nigra Nucleus Accumbens Stereotyped Behaviour Locomotor Response Spontaneous Locomotor Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agid, Y., Javoy, F., Glowinski, J., Bovert, D. and Sotelo, C.: Injection of 6-hydroxydopamine into the substantia nigra of the rat. II. Diffusion and specificity, Brain Res. 58, 291–301 (1973).PubMedCrossRefGoogle Scholar
  2. Anden, N.E. and Stock, G.: Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system, J. Pharm. Pharmac. 25, 346–348 (1973).CrossRefGoogle Scholar
  3. Breese, G.R. and Traylor, T.D.: Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine, Br. J. Pharmacol. 42, 88–89 (1971).PubMedGoogle Scholar
  4. Burki, H.R., Rush, W., Asper, H., Baggiolini, N. and Stille, G.: Pharmakologische und neurochemische wirkungen von clozapin. Neue Gesichtspunkte in der medikamentosen Behandlung der Schizophrenie, Schweiz. med. Wschr. 103, 1716–1724 (1973).PubMedGoogle Scholar
  5. Cole, J.O. and Clyde, D.J.: Extrapyramidal side effects and clinical response to the phenothiazines, Revue Can. Biol. 20, 565–574 (1961).Google Scholar
  6. Costall, B. and Naylor, R.J.: Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine, Psychopharmacologia 43, 69–74 (1975).PubMedCrossRefGoogle Scholar
  7. Creese, I. and Iversen, S.D.: Amphetamine response after dopamine neurone destruction, Nature New Biol. 238, 247–248 (1972).PubMedGoogle Scholar
  8. Cuello, A., Hiley, R. and Iversen, L.L.: Use of catechol-0-methyltransferase for the enzyme radiochemical assay of dopamine, J. Neurochem. 21, 1337–1340 (1973).PubMedCrossRefGoogle Scholar
  9. Ellinwood, E.H.: Amphetamine psychosis: I. Description of the individuals and process, J. nerv. ment. Dis. 144, 273–283 (1967).CrossRefGoogle Scholar
  10. Glowinski, J. and Baldessarini, R.J.: Metabolism of norepinephrine in the central nervous system, Pharmac. Rev. 18, 1201–1238 (1966).Google Scholar
  11. Groppetti, A., Zambotti, F., Biazzi, A. and Mantegazza, P.: Amphetamine and cocaine on amine turnover. In: Frontiers in Catecholamine Research. Usdin, E. and Snyder, S.H., Eds., pp. 917–925. Oxford: Pergamon Press, 1973.Google Scholar
  12. Hendry, I.A. and Iversen, L.L.: Effect of nerve growth factor and its antiserum on tyrosine hydroxylase activity in mouse superior cervical sympathetic ganglion, Brain Res. 29, 159–162 (1971).PubMedCrossRefGoogle Scholar
  13. Iversen, S.D. and Kelly, P.H.: The use of 6-hydroxydopamine (6-OHDA) techniques for studying the pathways involved in drug-induced motor behaviours. In: Chemical Tools in Catecholamine Research. New York: Elsevier, in press.Google Scholar
  14. Kelly, P.H. and Miller, R.J The interaction of neuroleptic and muscarinic agents with central dopaminergic systems, Bt.J. Pharmacol. 54, 115–121 (1975).Google Scholar
  15. Kelly, P.H., Seviour, P.W. and Iversen, S.D.: Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum, Brain Res. 94, 507–522 (1975).PubMedCrossRefGoogle Scholar
  16. Miller, R.J. and Hiley, C.R.: Antimuscarinic properties of neuroleptic drugs and drug induced parkinsonism, Nature, Lond. 248, 596–597 (1974).CrossRefGoogle Scholar
  17. Pijnenburg, A.J.J. and van Rossum, J.M.: Stimulation of locomotor activity following injection of dopamine into the nucleus accumbens, J. Pharm. Pharmac. 25, 1003–1005 (1973).CrossRefGoogle Scholar
  18. Rylander, G.: Clinical and medico-criminological aspects of addictions to central stimulating drugs. In: Abuse of Central Stimulants. Sjoquist, F. and Tottie, M., Eds., pp. 251–273. New York: Raven Press, 1969.Google Scholar
  19. Simon, P.: Psychopharmacological profile of cocaine. In: Fron-tiers of Catecholamine Research. Usdin, E. and Snyder, S.H., Eds., pp. 1043–1044. Oxford: Pergamon Press, 1973.Google Scholar
  20. Snyder, S. H.: Catecholamines in the brain as mediators of ampheta- mine psychosis, Arch. gen. Psychiat. 27, 169–179 (1972).PubMedCrossRefGoogle Scholar
  21. Sotelo, C., Javoy, F., Agid, Y. and Glowinski, J.: Injection of 6-hydroxydopamine in the substantia nigra of the rat. I. Morphological study, Brain Res. 58, 269–290 (1973).PubMedCrossRefGoogle Scholar
  22. Ungerstedt, U.: Stereotaxic mapping of the monoamine pathway in the rat brain, Acta Physiol. Scand. 83, Suppl. 367, 49–68 (1971).Google Scholar
  23. Ungerstedt, U. and Arbuthnott, G.: Quantitative recording of rotational behaviour in rats after 6-OH dopamine lesions of the rat nigrostriatal dopamine system, Brain Res. 24, 486–493 (1970).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • Susan D. Iversen
    • 1
  1. 1.Department of PsychologyCambridgeEngland

Personalised recommendations